Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer’s perspective | BMC Cancer User montaukwhaler, in the non small cell lung cancer subreddit, 31 Mar 2018